Clover Health Investments, Corp. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Clover Health operates Medicare Advantage PPO and HMO plans through regulated insurance subsidiaries and uses its Clover Assistant technology platform to support physician decision-making and chronic disease management. At March 31, 2024, the company operated in five states and 200 counties and had 79,527 members, compared with 83,794 at March 31, 2023.
The filing covers the three months ended March 31, 2024. Beginning in 2024, the company reports one operating segment, Insurance. The former ACO REACH/Non-Insurance business is presented as discontinued operations following Clover’s exit from the program for the 2024 performance year.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Premiums earned, net | $341.7 million | $317.1 million | +7.8% |
| Total revenues | $346.9 million | $322.0 million | +7.7% |
| Net medical claims incurred | $265.2 million | $274.8 million | -3.5% |
| Medical care ratio, net | 77.9% | 86.6% | Improved 8.7 points |
| Loss from continuing operations | $22.7 million | $79.7 million | Improved $57.0 million |
| Net loss from continuing operations | $23.2 million | $79.7 million | Improved $56.5 million |
| Net income from discontinued operations | $4.0 million | $7.1 million | -43.6% |
| Consolidated net loss | $19.2 million | $72.6 million | Improved $53.4 million |
| Net loss per share from continuing operations | $0.05 | $0.17 | Improved |
Gross profit increased to $81.8 million from $47.2 million. Based on reported figures, consolidated gross profit as a percentage of total revenue was approximately 23.6%, compared with 14.7% in the prior-year quarter. The company reported no material debt or material changes to financing arrangements compared with its 2023 Form 10-K.
Cash flow, liquidity, and balance sheet
- Net cash provided by operating activities was $25.9 million, compared with $79.0 million in Q1 2023.
- Net cash provided by investing activities was $9.2 million, primarily reflecting $33.7 million of investment maturities offset by $24.1 million of investment purchases.
- Net cash used in financing activities was $3.4 million, primarily for treasury stock purchases.
- Cash and cash equivalents were $208.3 million at March 31, 2024, compared with $116.4 million at December 31, 2023.
- Total cash, cash equivalents, restricted cash, and investments were $440.3 million at March 31, 2024, compared with $417.3 million at year-end 2023.
- Total assets were $671.8 million and total liabilities were $379.3 million; stockholders’ equity was $292.5 million.
- Unpaid claims increased to $238.6 million from $135.7 million at year-end 2023. Management attributed the increase largely to slower claims processing following a third-party cyber incident.
- Management expects available cash, investments, and projected operating cash flows to satisfy projected operating and regulatory requirements for at least the next 12 months, but notes that additional financing could be required depending on business needs and unforeseen circumstances.
Material changes versus the prior comparable period
- Premiums increased primarily because of favorable risk-adjustment revenue and a focus on member retention.
- Medical claims declined despite higher premiums, resulting in a significant improvement in the medical care ratio.
- Salaries and benefits declined 14.1% to $59.2 million, primarily because of lower stock-based compensation.
- General and administrative expenses declined 22.7% to $44.6 million, primarily due to lower live healthy program and broker commission expenses.
- Restructuring costs declined to $0.4 million from $1.8 million. Cumulative restructuring costs related to the UST HealthProof transition and related initiatives were $10.2 million at March 31, 2024.
- Stock-based compensation remained significant at $28.8 million, with approximately $421.0 million of unrecognized expense expected to be recognized over approximately four years.
- The company recognized $0.5 million of losses from its equity-method investment in Character Biosciences.
- Discontinued-operations revenue fell to $6.8 million from $205.8 million because the ACO REACH business was exited and remaining activity relates primarily to prior performance-year settlement matters.
Guidance, outlook, risks, contingencies, and unusual items
- No formal revenue or earnings guidance is provided in the filing.
- CMS awarded both the PPO and HMO plans 3.0 Stars for the 2022 measurement year, down 0.5 Stars from the prior measurement year. The rating affects the 2025 payment year; 2024 payments are based on the previously awarded 3.5-Star ratings.
- The company expects settlement of remaining ACO REACH obligations with CMS during the second half of 2024. The maximum potential future payment under related performance guarantees cannot be estimated clearly because of stop-loss arrangements, corridors, risk ratings, and benchmark trends.
- At March 31, 2024, discontinued-operations liabilities included a $9.7 million ACO performance-year obligation and $39.8 million of other Non-Insurance payables.
- The company received a Nasdaq notice on April 2, 2024 for failure to maintain a $1.00 minimum bid price. It has until September 30, 2024 to regain compliance and may pursue an additional compliance period or a reverse stock split. Delisting could materially impair trading liquidity and the stock price.
- The company continues to cooperate with an SEC investigation related to matters disclosed in 2021. A related securities class action was settled for $22 million, funded in part by $19.5 million of insurance proceeds. Derivative litigation settlements remain subject to court approval and include proposed governance enhancements and $2.5 million of plaintiffs’ counsel fees.
- Key operating risks include medical-cost and claims-reserve estimation risk, Medicare and healthcare regulation, CMS risk-adjustment and Star Rating changes, member retention, provider-network management, cyber incidents, regulatory capital restrictions, litigation, interest-rate and investment risk, and potential future financing needs.
- On May 6, 2024, the board authorized repurchases of up to $20 million of Class A common stock over two years; the timing and amount of repurchases are discretionary and not guaranteed.
Important facts investors should verify
- Whether the improved 77.9% medical care ratio is sustained after claims-processing disruptions normalize.
- The adequacy and timing of unpaid-claims reserves, particularly given the $102.4 million quarterly increase and third-party cyber incident.
- The final CMS settlement amount and timing for remaining ACO REACH obligations.
- Progress toward regaining Nasdaq’s minimum bid-price compliance by September 30, 2024 and any reverse-stock-split action.
- The effect of the 3.0-Star ratings on 2025 Medicare Advantage revenue and margins.
- Availability of cash at the parent and regulated subsidiaries, considering restrictions on dividends from regulated insurance subsidiaries.
- The company’s ability to reduce recurring losses while managing substantial future stock-based compensation expense and potential capital requirements.